Features | Healtcare News | BioTuesdays by Kilmer Lucas IR

This Week's Feature

MindMed driving therapeutic potential of psychedelics for brain health disorders

MindMed (NASDAQ:MNMD; NEO:MMED) is advancing a pipeline of psychedelic and next generation drug candidates to treat brain health disorders, with a particular focus on psychiatry, addiction, pain and neurology.

May 24, 2022

Feature

Lanier Biotherapeutics joins Big Pharma advancing first-in-class Type 2 and non-Type 2 anti-inflammatory biologic

Closely-held Lanier Biotherapeutics is pioneering a first-in-class Type 2 and non- Type2 anti-inflammatory biologic, LNR 125, as a new candidate targeting treatments commonly associated with Type 2 inflammation like...

May 17, 2022

Feature

Qualigen advancing platform technologies in therapeutics and diagnostics

Backed by a commercial diagnostics business, Qualigen Therapeutics (NASDAQ:QLGN) has broadened its focus to developing platform therapeutics for cancer with potential orphan drug designation.

May 10, 2022

Feature

Talking mental health with Chris Wang of Shimmer

Chris Wang, Co-founder and CEO of Shimmer As co-founder and CEO of Shimmer, a provider of a science-backed process to reduce stress and anxiety, Chris Wang took an early interest in social impact consulting at her first...

May 3, 2022

Feature

Claritas Pharmaceuticals transforming nitric oxide therapy

Claritas Pharmaceuticals (TSXV:CLAS; OTC:CLAZF) is developing R-107, a liquid drug candidate that may hold the key to transforming nitric oxide therapy from its current gaseous inhalation method of delivery to...

April 26, 2022

Feature

Know Labs non-invasive paradigm shift takes measurements inside the body

Know Labs (OTCQB:KNWN) is transforming non-invasive medical diagnostics with its Bio-RFID technology platform that uses electromagnetic energy in the form of radio waves to identify and measure what’s going on inside...

April 19, 2022

Feature

In conversation with Dr. Murat Kalayoglu of Cartesian

As president and CEO of closely-held Cartesian Therapeutics, Murat Kalayoglu, M.D., Ph.D., has made a smooth transition over the years from a board-certified ophthalmologist to a healthcare IT entrepreneur to a medical...

April 12, 2022

Feature

Cocrystal Pharma advancing programs in high-value antiviral drug targets

With a drug discovery technology platform developed by several Nobel Prize laureates, Cocrystal Pharma (NASDAQ:COCP) is advancing broad spectrum antivirals in three programs: coronaviruses and variants, pandemic and...

April 5, 2022

Feature

180 Life Sciences focused on one of largest drivers of disease: inflammation

180 Life Sciences (NASDAQ:ATNF) has three families of novel biologic drugs in synchronized stages of development, addressing separate areas of inflammation, fibrosis and pain, for which there are no effective therapies.

March 29, 2022

Feature

First Wave developing targeted, non-systemic therapies for GI diseases

First Wave BioPharma (NASDAQ:FWBI) is advancing multiple clinical-stage programs built around its two proprietary technologies: niclosamide, an oral small molecule with anti-viral and anti-inflammatory properties, and a...

March 22, 2022

Feature

Transforming biologic drug discovery with Sean McClain of Absci

As CEO and founder of Absci (NASDAQ:ABSI), a drug and target discovery company harnessing deep learning AI and synthetic biology to expand the therapeutic potential of proteins, Sean McClain has come a long way in the...

March 15, 2022

Feature

Ampio to seek FDA agreement on modified intent-to-treat BLA in severe OAK

Ampio Pharmaceuticals (NYSE American:AMPE), citing a significant impact from COVID-19 on its second confirmatory Phase 3 trial of Ampion for the treatment of severe osteoarthritis of the knee (OAK), hopes to meet with...

March 8, 2022

Feature

Precigen advancing pipeline of gene and cell therapies in I-O, autoimmune, infectious disorders

Precigen (NASDAQ:PGEN) is advancing a pipeline of next generation gene and cell therapies using precision technology in its core therapeutic areas of immuno-oncology, autoimmune disorders, and infectious diseases.

March 1, 2022

Feature

Palisade Bio guarding against post-operative disruption of GI function

Palisade Bio (NASDAQ:PALI) is advancing therapies that help patients with acute and chronic GI complications, stemming from post-operative tissue damage, to speed recovery and reduce hospital stays.

February 22, 2022

Feature

Sigyn Therapeutics hopes to file IDE in Q2 for human studies of Sigyn Therapy

Sigyn Therapeutics (OTC:SIGY) hopes to file in the second quarter this year an investigational device exemption (IDE) with the FDA to initiate human clinical studies of its Sigyn Therapy, a dual-function blood...

February 15, 2022

Feature

Athira Pharma advancing new therapies for neurodegeneration, neuronal health

Athira Pharma (NASDAQ:ATHA) is in late- and mid-stage clinical development of small molecules to restore neuronal health and slow neurodegeneration of diseases, such as Alzheimer’s, Parkinson’s and dementia.

February 8, 2022

Feature

Zucara awaiting proof-of-concept data to prevent insulin-induced hypoglycemia in people with diabetes

Closely-held Zucara Therapeutics expects to release results in the second quarter of its Phase 1b proof-of-concept study with its once-daily drug candidate, ZT-01, to prevent insulin-induced hypoglycemia, or low blood...

February 1, 2022

Feature

Aravive developing targeted cancer therapeutics to treat metastatic disease

Aravive (NASDAQ:ARAV) is taking a differentiated approach with its lead molecule, batiraxcept, to target inhibition of the GAS6/AXL signaling pathway in several cancer indications.

January 25, 2022

Feature

POINT Biopharma creating platform for next-generation radiopharmaceuticals

POINT Biopharma Global (NASDAQ:PNT) is accelerating the development of precision medicines for the treatment of cancer, with a late- and early-stage pipeline of radiopharmaceuticals, a technology platform for pipeline...

January 18, 2022

Feature

ENDRA’s TAEUS enhancing ultrasound to measure fatty liver disease NAFLD-NASH

ENDRA Life Sciences (NASDAQ:NDRA) has developed a novel assessment tool – Thermo Acoustic Enhanced Ultrasound (TAEUS) – to enhance existing ultrasound systems and provide capabilities that are available with MRI, but at...

January 11, 2022

Feature

Illuminate Health offering pharmacist-led virtual medication management

Closely-held Illuminate Health is leveraging a technology-enabled continuous medication management platform to help patients optimize medications at home to improve treatment adherence and reduce hospitalizations.

January 4, 2022

This Week's Feature

Annovis Bio improving information highway of nerve cells to treat AD, PD

Annovis Bio (NYSE:ANVS) is developing a lead drug candidate, ANVS401, to inhibit more than one neurotoxic protein, improving the information highway of nerve cells, known as axonal transport, for the treatment of...

December 14, 2021

MindMed driving therapeutic potential of psychedelics for brain health disorders

Lanier Biotherapeutics joins Big Pharma advancing first-in-class Type 2 and non-Type 2 anti-inflammatory biologic

Qualigen advancing platform technologies in therapeutics and diagnostics

Talking mental health with Chris Wang of Shimmer

Claritas Pharmaceuticals transforming nitric oxide therapy

Know Labs non-invasive paradigm shift takes measurements inside the body

In conversation with Dr. Murat Kalayoglu of Cartesian

Cocrystal Pharma advancing programs in high-value antiviral drug targets

180 Life Sciences focused on one of largest drivers of disease: inflammation

First Wave developing targeted, non-systemic therapies for GI diseases

Transforming biologic drug discovery with Sean McClain of Absci

Ampio to seek FDA agreement on modified intent-to-treat BLA in severe OAK

Precigen advancing pipeline of gene and cell therapies in I-O, autoimmune, infectious disorders

Palisade Bio guarding against post-operative disruption of GI function

Sigyn Therapeutics hopes to file IDE in Q2 for human studies of Sigyn Therapy

Athira Pharma advancing new therapies for neurodegeneration, neuronal health

Zucara awaiting proof-of-concept data to prevent insulin-induced hypoglycemia in people with diabetes

Aravive developing targeted cancer therapeutics to treat metastatic disease

POINT Biopharma creating platform for next-generation radiopharmaceuticals

ENDRA’s TAEUS enhancing ultrasound to measure fatty liver disease NAFLD-NASH

Illuminate Health offering pharmacist-led virtual medication management

Annovis Bio improving information highway of nerve cells to treat AD, PD

General

More